Iradimed (IRMD) Stock Price, News & Analysis

Company Overview

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.

Key Stats

• Today's Range: $52.90 to $55.15
• 50-Day Range: $48.30 to $57.35
• 52-Week Range: $40.18 to $57.95
• Volume: 90,292 shs
• Average Volume: 48,832 shs
• Market Capitalization: $692.58 million
• P/E Ratio: 37.43
• Dividend Yield: 1.10%
• Price Target: $60.00
• Consensus Rating: Buy

Iradimed Stock Analysis - MarketRank™

Iradimed scored higher than 88% of companies evaluated by MarketBeat, and ranked 147th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Buy

Consensus Rating

Iradimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Iradimed has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 4.61%

Earnings Growth

Earnings for Iradimed are expected to grow by 4.61% in the coming year, from $1.52 to $1.59 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Iradimed is 37.43, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 114.00.

Price to Earnings Ratio vs. Sector

The P/E ratio of Iradimed is 37.43, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 91.34.

Price to Book Value per Share Ratio

Iradimed has a P/B Ratio of 9.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.08% of the float of Iradimed has been sold short.

Short Interest Ratio / Days to Cover

Iradimed has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Iradimed has recently increased by 0.23%, indicating that investor sentiment is decreasing.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Iradimed pays a meaningful dividend of 1.13%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Iradimed does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Iradimed is 41.10%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Iradimed will have a dividend payout ratio of 37.74% next year. This indicates that Iradimed will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -0.85

Percentage of Shares Shorted

1.08% of the float of Iradimed has been sold short.

Short Interest Ratio / Days to Cover

Iradimed has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Iradimed has recently increased by 0.23%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.77

News Sentiment

Iradimed has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Iradimed this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for IRMD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Iradimed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $135,450.00 in company stock.

Percentage Held by Insiders

37.10% of the stock of Iradimed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

92.34% of the stock of Iradimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IRMD Stock Analysis - Frequently Asked Questions

How have IRMD shares performed this year?

Iradimed's stock was trading at $47.47 on January 1st, 2024. Since then, IRMD stock has increased by 15.1% and is now trading at $54.65.
View the best growth stocks for 2024 here.

How were Iradimed's earnings last quarter?

Iradimed Corporation (NASDAQ:IRMD) released its quarterly earnings results on Thursday, August, 1st. The medical equipment provider reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.05. The medical equipment provider earned $17.93 million during the quarter, compared to the consensus estimate of $17.70 million. Iradimed had a trailing twelve-month return on equity of 23.99% and a net margin of 26.12%.

Who are Iradimed's major shareholders?

Iradimed's top institutional shareholders include Copeland Capital Management LLC (3.34%), Geode Capital Management LLC (1.49%), State Street Corp (1.31%) and HighTower Advisors LLC (0.65%). Insiders that own company stock include Roger E Susi, James B Hawkins, Monty K Allen, Anthony Vuoto, John Glenn and Christopher K Scott.
View institutional ownership trends.

How do I buy shares of Iradimed?

Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Iradimed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Iradimed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 8/01/2024
• Ex-Dividend for 11/25 Dividend: 11/15/2024
• Dividend Payable: 11/25/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:IRMD
• CUSIP: N/A
• CIK: 1325618
• Web: www.iradimed.com
• Phone: (407) 677-8022
• Fax: 407-677-5037
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $60.00
• High Stock Price Target: $60.00
• Low Stock Price Target: $60.00
• Potential Upside/Downside: +9.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $1.46
• Trailing P/E Ratio: 37.43
• Forward P/E Ratio: 35.95
• P/E Growth: N/A
• Net Income: $17.19 million
• Net Margins: 26.12%
• Pretax Margin: 33.11%
• Return on Equity: 23.99%
• Return on Assets: 20.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.21
• Quick Ratio: 7.82

Sales & Book Value

• Annual Sales: $71.31 million
• Price / Sales: 9.71
• Cash Flow: $1.41 per share
• Price / Cash Flow: 38.75
• Book Value: $5.66 per share
• Price / Book: 9.66

Miscellaneous

• Outstanding Shares: 12,673,000
• Free Float: 7,971,000
• Market Cap: $692.58 million
• Optionable: Optionable
• Beta: 0.82